Progression of Aortic Calcification in Stage 4–5 Chronic Kidney Disease Patients Transitioning to Dialysis and Transplantation

Roosa Lankinen\textsuperscript{a} Markus Hakamäki\textsuperscript{a} Tapio Hellman\textsuperscript{a} Niina S. Koivuvii\textsuperscript{a} Kaj Metsärinne\textsuperscript{a} Mikko J. Järvisalo\textsuperscript{a, b, c}

\textsuperscript{a}Kidney Centre, Turku University Hospital and University of Turku, Turku, Finland; \textsuperscript{b}Department of Anaesthesiology and Intensive Care, University of Turku, Turku, Finland; \textsuperscript{c}Perioperative Services, Intensive Care and Pain Medicine, Turku University Hospital, Turku, Finland

\textbf{Keywords}
Cardiovascular disease · Chronic kidney disease · Aortic calcification

\textbf{Abstract}

\textbf{Background and Aims:} Abdominal aortic calcification (AAC) is common in chronic kidney disease (CKD) patients and associated with increased mortality. Comparative data on the AAC score progression in CKD patients transitioning from conservative treatment to different modalities of renal replacement therapy (RRT) are lacking and were examined.

\textbf{Methods:} 150 study patients underwent lateral lumbar radiograph to study AAC in the beginning of the study before commencing RRT (AAC1) and at 3 years of follow-up (AAC2). We examined the associations between repeated laboratory tests taken every 3 months, echocardiographic and clinical variables and AAC increment per year ($\Delta$AAC), and the association between $\Delta$AAC and outcomes during follow-up.

\textbf{Results:} At the time of AAC2 measurement, 39 patients were on hemodialysis, 39 on peritoneal dialysis, 39 had a transplant, and 33 were on conservative treatment. Median AAC1 was 4.8 (0.5–9.0) and median AAC2 8.0 (1.5–12.0) ($p = 0.0001$). $\Delta$AAC was similar across the treatment groups ($p = 0.19$). $\Delta$AAC was independently associated with mean left ventricular mass index (LVMI) (log LVMI: $\beta = 0.97$, $p = 0.02$) and mean phosphorus through follow-up (log phosphorus: $\beta = 1.19$, $p = 0.02$) in the multivariable model. Time to transplantation was associated with $\Delta$AAC in transplant recipients (per month on the waiting list: $\beta = 0.04$, $p = 0.001$). $\Delta$AAC was associated with mortality (HR 1.427, 95% confidence interval 1.044–1.950, $p = 0.03$).

\textbf{Conclusion:} AAC progresses rapidly in patients with CKD, and $\Delta$AAC is similar across the CKD treatment groups including transplant recipients. The increment rate is associated with mortality and in transplant recipients with the time on the transplant waiting list.

© 2021 The Author(s). Published by S. Karger AG, Basel

\section*{Introduction}

Patients with chronic kidney disease (CKD) are at remarkably high risk for cardiovascular events and death [1]. Atherosclerosis and arterial calcification often progress rapidly in CKD patients, a phenomenon which is inadequately explained by traditional risk factors such as diabetes, smoking, obesity, dyslipidemia, and hypertension [2]. CKD-mineral and bone disorder (CKD-MBD)
syndrome leads to arterial calcification, which is further augmented by progression of CKD [3]. In end-stage kidney disease, vascular calcification (VC) is characterized by mineral deposition in the tunica media of the arterial wall. Previous data suggest that the pathophysiological mechanism of VC is a dynamic process, rather than passive mineral precipitation [4].

The abdominal aortic calcification (AAC) score is independently associated with cardiovascular events and death in the general population and in dialysis patients [5–7], and thus current guidelines recommend the evaluation of AAC in CKD [3]. Furthermore, previous studies in moderate CKD, maintenance dialysis, and kidney transplant patients have shown that VC is common and progresses even following successful kidney transplantation [8, 9]. In fact, Noordzij and coworkers demonstrated progression of aortic calcification in almost a third of 384 patients on maintenance hemodialysis (HD) or peritoneal dialysis (PD) during a mean follow-up of 2.3 years, and progressed calcification was significantly associated with mortality [10]. Some previous studies have linked accelerated progression of VC with hypercalcemia and hyperparathyroesia in maintenance dialysis patients [10, 11]. Most previous prospective studies have however examined the progression of AAC in patients already on maintenance dialysis or in patients with prior kidney transplantation, whereas data on AAC progression in CKD stage 4–5 patients transitioning from conservative treatment to different modalities of renal replacement therapy (RRT) are lacking.

Therefore, we aimed to study progression of AAC, associated risk factors, and outcomes in CKD stage 4–5 patients transitioning to dialysis and kidney transplantation. Furthermore, the aim of the study was to compare AAC progression between different modalities of RRT.

Materials and Methods

Study Protocol

Two hundred ten consecutive patients referred to the Kidney Centre Predialysis Outpatient Clinic of Turku University Hospital were recruited between August 2013 and September 2017 in the Chronic Arterial Disease, quality of life and mortality in chronic KIDney injury (CADKID) study. The study population target was set to a minimum of 200 patients in the beginning of the recruitment. CADKID is an ongoing, prospective, follow-up study assessing arterial disease, quality of life, mortality, and their predictors in patients with CKD (KD-DKDIGO 4–5) (http://www.Clinical-Trials.gov NCT04223726) [12]. CKD stage 4–5 patients are followed up regularly at 1- to 2-month intervals at the Kidney Centre Predialysis Outpatient Clinic. The individual patient data were collected from the research hospital’s patient documents and during study and clinical control visits. The data from hospital software were combined and the patient identity numbers removed before the statistical analyses.

The present study is a prespecified report from the CADKID study aiming to examine the progression of calcification and associated risk factors including the treatment modality for CKD. At least one AAC measurement was available in 199 patients, and 150 patients had 2 consecutive AAC measurements and comprised the study cohort. The CADKID study baseline imaging data including baseline AAC measurements have been previously published [12]. Laboratory variables including blood hemoglobin, leukocytes, thrombocytes, glycated hemoglobin, pH, bicarbonate and base excess, plasma C-reactive protein, glucose, alanine aminotransferase, alkaline phosphatase, creatinine, urea, albumin, sodium, potassium, phosphorus, total and ionized calcium and parathyroid hormone (PTH), and serum lipids were collected and recorded every 3 months from the beginning of the study spanning to the second AAC imaging in every patient. The estimated glomerular filtration rate (eGFR) was calculated using the Chronic Kidney Disease Epidemiology Collaboration equation. Major adverse cardiovascular events (MACEs) defined as a composite of cardiovascular death, myocardial infarction, stroke, and coronary artery revascularization were recorded.

Assessment of AAC

Lateral lumbar radiography was performed in the standing position using standard radiographic equipment in the beginning of the study and at 3 years of follow-up. At our center, the measurement of AAC from lateral lumbar radiographs is part of standard clinical assessment in CKD patients when considering their eligibility to the transplant waiting list. Calcification of the abdominal aorta was graded using a previously validated system in the region corresponding to the first through the fourth lumbar vertebrae [13]. Both the location and the severity of calcific deposits at each lumbar vertebral segment were evaluated. Lesions were graded as follows: 0, no aortic calcific deposits; 1, small scattered calcific deposits filling <1/3 of the longitudinal wall of the aorta; 2, calcific lesions filling 1/3 or more but less than 2/3 of the longitudinal aortic wall; and 3, two-thirds or more of the longitudinal wall of the aorta calcified (online suppl. Fig. 1; for all online suppl. material, see www.karger.com/doi/10.1159/000518670). In the anteroposterior severity score (0–24), the scores of individual aortic segments both for the posterior and anterior wall were summed. All radiographs were read independently by 2 researchers, and the mean AAC score was used in the analyses. The intra- and interobserver variations (CVs) of AAC measurements were 4.8% and 11.5%, and the mean differences between measurements 0.5 and 1.0 points, respectively. AAC increment per year (AAAC) was defined as: (follow-up AAC [AAC2] − baseline AAC [AAC1])/time between AAC1 and AAC2 assessments (years).

Echocardiography

The echocardiographic measures were collected from standardized transthoracic echocardiography performed in the beginning of the study and repeated at 3 years of follow-up (available in 143 patients). The systolic and diastolic dimensions and function of the left ventricle as well as left ventricular wall thicknesses were measured. The left ventricular mass index (LVMI) was calculated using the following equations: LVMI = left ventricular mass/body.
Table 1. Demographic, clinical, laboratory, and echocardiographic characteristics

| Variable                              | Value                        |
|---------------------------------------|------------------------------|
| Number of subjects, female, n (%)     | 150 (52)                     |
| Age, years                            | 61 (49–72)                   |
| Diabetes, n (%)                       | 65 (43)                      |
| Coronary artery disease, n (%)        | 17 (11)                      |
| Antihypertensive medication, n (%)    | 147 (98)                     |
| BMI, kg/m²                            | 27.7 (24.0–30.9)             |
| Systolic blood pressure, mm Hg        | 146±16                       |
| Diastolic blood pressure, mm Hg       | 79±10                        |
| Pulse pressure, mm Hg                 | 67±16                        |
| eGFR, mL/min/1.73 m²                  | 12 (11–15)                   |
| Creatinine, μmol/L                    | 433 (364–547)                |
| Urea, mmol/L                          | 20.4±4.9                     |
| Hemoglobin, g/L                       | 114 (109–121)                |
| CRP, mg/L                             | 3.3 (1.8–6.7)                |
| Albumin, g/L                          | 33.4±3.4                     |
| Sodium, mmol/L                        | 141 (139–142)                |
| Potassium, mmol/L                     | 4.3±0.3                      |
| Ionized calcium, mmol/L               | 1.22±0.06                    |
| Phosphorus, mmol/L                    | 1.44 (1.30–1.63)             |
| PTH, ng/L                             | 234 (159–339)                |
| pH                                    | 7.36±0.03                    |
| Bicarbonate, mmol/L                   | 23.3±2.3                     |
| Alkaline phosphatase, U/L             | 75 (65–92)                   |
| Total cholesterol, mmol/L             | 4.2 (3.5–5.0)                |
| Low-density lipoprotein cholesterol, mmol/L | 2.3 (1.6–3.0) |
| High-density lipoprotein cholesterol, mmol/L | 1.2 (1.0–1.5) |
| Triglycerides, mmol/L                 | 1.5 (1.1–2.0)                |
| HbA1c, mmol/mol                       | 37 (32–50)                   |
| Ejection fraction, n (%)              | 65 (62–68)                   |
| LVDD, mm                               | 53.3±5.1                     |
| LVMI, g/m²                             | 102 (88–119)                 |

Values are presented as mean ± SD for normally distributed variables and median (IQR) for skewed variables. Laboratory variables are mean/median of mean values for measurements taken every 3 months from study recruitment to the control AAC imaging and echocardiographic measures are a mean of 2 consecutive assessments. Blood pressure measurements shown are a mean of all measurements during the study period. eGFR, estimated glomerular filtration rate; CRP, C-reactive protein; BMI, body mass index; PTH, parathyroid hormone; LVDD, left ventricular end-diastolic diameter; LVMI, left ventricular mass index; AAC, abdominal aortic calcification; SD, standard deviation; IQR, interquartile range.

Statistical Analysis

Results are presented as mean ± standard deviation for the normally distributed variables and as median (interquartile range) for skewed variables. Normality in continuous covariates was tested with Kolmogorov-Smirnov and Shapiro-Wilk tests. Skewed variables were loge-transformed to normalize distributions. Comparisons between AAC1 and AAC2 were done using the Wilcoxon signed-rank test. Differences between the treatment groups (conservative treatment, PD, HD, and kidney transplant) in ΔAAC were examined using a nonparametric Kruskal-Wallis test, followed by the Dwass-Steel-Critchlow-Fligner method for pair-wise comparisons [14]. The mean of the 2 consecutive echocardiographic measurements was used in the analyses for echocardiographic measures, and the mean of blood pressure measurements during the study period was used for blood pressure. The mean of all consecutive laboratory measurements (3 months apart), respectively, was used in the analyses. Univariate and multivariable associations between exposure variables and ΔAAC were examined using linear regression models. First, the associations between ΔAAC and exposure variables were studied using respective univariate models. Laboratory variables were included as mean values during the interval between AAC1 and AAC2 assessments in the respective univariate models. The significant univariate exposure variables for ΔAAC, namely, phosphorus, albumin, LVMI, pulse pressure, and smoking status (nonsmoker, ex-smoker, and current smoker) were included in the multivariable model. Potential existence of multicollinearity was assessed by examining variance inflation factors. Associations between ΔAAC and outcomes were examined using univariate Cox proportional hazards models. The low number of all-cause mortalities did not allow for multivariable models.

All statistical analyses were performed using statistical analysis system, SAS version 9.3 (SAS Institute Inc., Cary NC). A p value <0.05 was considered statistically significant.

Results

A total of 150 patients of the CADKID study population had 2 consecutive AAC measurements (baseline: AAC1; follow-up: AAC2). The median interval between AAC measurements was 37 (29–44) months. Clinical,
laboratory, and echocardiographic characteristics of study subjects are shown in Table 1 and medications at baseline in Table 2.

Patients were followed up for 5.0 ± 1.4 years. Fifteen patients (10%) died during the follow-up. MACEs were observed in 30 patients (22%) during the follow-up (myocardial infarction n = 9; stroke n = 8; coronary artery revascularization n = 13; no cardiovascular deaths without a prior MACE). At the time of the AAC2 assessment, 33 patients were followed up conservatively, 39 were on HD, 39 on PD, and 39 had received a kidney transplant (Fig. 1). Only one of the patients who remained on conservative care throughout the study period was considered ineligible for RRT initiation. The eGFR at AAC2 assessment was 13 ± 6 mL/min/1.73 m² in the conservative treatment group. In those who started HD or PD, the median time from dialysis initiation to AAC2 imaging was 19 (15–27) months, and in transplanted patients, the time from transplantation was 14 (7–22) months. In the kidney transplant recipients, eGFR was 60 ± 23 mL/min/1.73 m² at the time of the AAC2 imaging.

The median AAC1 was 4.8 (0.5–9.0) and median AAC2 8.0 (1.5–12.0), (p < 0.0001). Altogether, the median ΔAAC was 0.48 (0.00–1.43) per year. The median ΔAAC was 0.41 (0.00–0.97) per year in conservatively treated patients, 0.34 (0.00–0.95) per year in transplanted patients, 0.53 (0.00–1.57) per year in HD patients, and 1.0 (0.0–1.83) per year in PD patients. The differences in ΔAAC between the groups were nonsignificant (p = 0.19) (Fig. 2). Patients without calcification at baseline (AAC = 0) had lower ΔAAC than patients with any calcification at baseline (0 [0–0] vs. 0.81 [0.26–1.61] per year, p < 0.0001). There was a significant but modest correlation between AAC1 and ΔAAC (r = 0.25, p = 0.002). The echocardiographic and blood pressure data by treatment group at baseline and at follow-up are given in online suppl. Table 1.
Patients who deceased during follow-up had higher AAC1 (8.5 [5.9–15.5] vs. 4.0 [0.0–8.5], \( p = 0.004 \)) and AAC2 (11.5 [8.5–18.0] vs. 7.0 [1.0–11.5], \( p = 0.003 \)) and higher \( \Delta \text{AAC} \) [1.67 (0.0–2.25) vs. 0.43 [0.0–1.27], \( p = 0.04 \)] than others. \( \Delta \text{AAC} \) (HR 1.427, 95% confidence interval [CI] 1.043–1.220, \( p = 0.03 \)), AAC1 (HR 1.128, 95% CI 1.043–1.220, \( p = 0.003 \)), and AAC2 (HR 1.140, 95% CI 1.050–1.237, \( p = 0.002 \)) were associated with all-cause mortality in univariate Cox proportional hazards models. AAC1 (HR 1.065 95% CI 0.921–1.549, \( p = 0.18 \)) and AAC2 (HR 1.067 95% CI 1.010–1.128, \( p = 0.02 \)) were associated with incident MACEs but \( \Delta \text{AAC} \) was not (HR 1.194 95% CI 0.921–1.549, \( p = 0.18 \)).

In univariate analysis, \( \Delta \text{AAC} \) was significantly associated with mean phosphorus (log phosphorus: \( \beta = 1.79, p = 0.001 \)), mean albumin (\( \beta = -0.09, p = 0.0005 \)), mean LVMI (log LVMI: \( \beta = 1.43, p = 0.0005 \)), mean pulse pressure (\( \beta = 0.02, p = 0.009 \)), and smoking status (nonsmoker, ex-smoker, and current smoker: \( \beta = 0.31, p = 0.02 \)). Serum lipids, glycated hemoglobin, ionized or total calcium, PTH, or other repeated laboratory variables were not significantly associated with \( \Delta \text{AAC} \). In the multivariable model, the only significant explanatory variables for \( \Delta \text{AAC} \) were mean LVMI (log LVMI: \( \beta = 0.97, p = 0.02 \)) and phosphorus (log phosphorus: \( \beta = 1.19, p = 0.02 \)) (Table 3). The progression of LVMI was however not associated with \( \Delta \text{AAC} \) (data not shown).

The use of calcium-based phosphate binders or their dose was not associated with \( \Delta \text{AAC} \) nor was the use of non-calcium-based phosphate binders. Moreover, warfarin use was not associated with \( \Delta \text{AAC} \).

In those who had received a transplant, the time to transplantation from the beginning of the study was associated with \( \Delta \text{AAC} \) (per month on the waiting list: \( \beta = 0.04, p = 0.001 \)). However, the time from transplantation to the AAC2 imaging was not associated with \( \Delta \text{AAC} \) (\( \beta = -0.000, p = 0.53 \)), and in dialysis patients, the duration of dialysis therapy was not associated with \( \Delta \text{AAC} \) (\( \beta = 0.009, p = 0.48 \)).

**Table 3. Univariate and multivariable associations between risk factors and \( \Delta \text{AAC} \)**

| Variable                      | Univariate analysis | Multivariate analysis |
|------------------------------|---------------------|-----------------------|
| Mean phosphorus, log         | 1.79 0.001          | 1.19 0.02             |
| Mean albumin, g/L            | -0.09 0.0005        | -0.04 0.17            |
| Mean LVMI, log               | 1.43 0.0005         | 0.97 0.02             |
| Smoking status               | 0.31 0.02           | 0.19 0.16             |
| Mean pulse pressure, mm Hg   | 0.02 0.009          | 0.005 0.41            |

log, logarithmic transformation; smoking status (nonsmoker, ex-smoker, and current smoker). LVMI, left ventricular mass index; AAC, abdominal aortic calcification.

**Discussion**

The current study shows for the first time that AAC progression is similar in CKD stage 4–5 patients transitioning to different modalities of RRT or continuing conservative treatment during a median 3-year follow-up. The increase rate of AAC was independently associated with plasma phosphorus but not ionized calcium, PTH, alkaline phosphatase, serum lipids, glycated hemoglobin, or other laboratory variables examined every 3 months from the beginning of the study to the latter AAC assessment.

Several previous studies have assessed the progression of VC in patients with various stages of CKD and shown that calcification progresses rapidly in earlier stages of CKD, patients on maintenance dialysis, and even kidney transplant patients with functional grafts [10, 11, 15].
Cardiovascular disease is the leading cause of death in patients with advanced CKD and efforts to improve prognosis should be focused on its treatment and prevention [1]. Traditional risk factors explain only a part of the increased risk, and nonclassical kidney-specific variables contribute significantly. Cardiovascular risk is diminished by kidney transplantation, but nevertheless, cardiovascular sequelae remain the leading cause of death after transplantation [17, 18]. CKD-MBD syndrome has been implicated as a significant risk factor for arterial calcification, MACES, and mortality in CKD. Previous studies in advanced CKD including patients with or without maintenance dialysis and kidney transplant recipients have shown that increased calcium, phosphorus, and PTH levels are associated with accelerated progression of aortic calcification [9–11, 15].

In the present study, plasma phosphorus was the only repeated laboratory variable independently associated with ΔAAC. Other laboratory variables associated with CKD-MBD such as PTH, total or ionized calcium, or alkaline phosphatase were not significantly associated with ΔAAC. Moreover, serum lipids, glycated hemoglobin, or C-reactive protein were not associated with ΔAAC, and the association between plasma albumin and ΔAAC became insignificant after adjusting for other explanatory variables in the multivariable model.

Although phosphorus levels even in the normal range have been established as an undisputed risk factor for cardiovascular and all-cause mortality in CKD by epidemiological studies [19], the few available randomized studies on the effects of phosphate-lowering interventions on VC have been disappointing. The potential benefits of phosphate-lowering therapy in patients with predialytic CKD remain to be demonstrated. However, most studies in CKD patients without maintenance dialysis have included patients with normal or only slightly elevated phosphorus levels at baseline. The reduction in phosphate observed with lanthanum carbonate, sevelamer, or calcium-based phosphate binders has been statistically insignificant, and no improvement in surrogate markers for arteriosclerosis or VC has been observed [20–22]. Conversely, in maintenance dialysis patients, recent meta-analyses have demonstrated a benefit for non-calcium-based phosphate binders for managing hyperphosphatemia with a parallel reduction in VC and mortality [23, 24]. Therefore, patients with apparent baseline VC and advanced CKD soon transitioning to RRT may benefit from assessment of CKD-MBD and management of hyperphosphatemia to limit the progression of VC.

Left ventricular hypertrophy has been associated with extra-coronary atherosclerosis and VC in maintenance HD patients [25], and the prevalence of left ventricular hypertrophy is high in CKD. Arteriosclerosis increases the stiffness of the aorta and large capacitance arteries, leading to left ventricular hypertrophy via pressure overload. In the present study however, the progression of LVMI during the study period was not associated with ΔAAC, although mean LVMI was.

The current study has limitations. First, the study was conducted in a single center, and the sample size was
somewhat limited. Assessing aortic calcification on the basis of plain radiographs may overlook some elusive calcifications and changes compared with CT techniques. However, intra- and interobserver reproducibility of the AAC measurements were acceptable. In comparison to previous studies, our study setting made it possible to compare AAC progression between different modalities of RRT and led to the novel finding that AAC progression during the early years following kidney transplantation is similar to that observed in patients initiating maintenance dialysis or continuing on conservative treatment. As the primary aim of the study was to examine the development of AAC and associated risk factors in CKD stage 4–5 patients transitioning to RRT or continuing on conservative care, we only included patients with ≥2 consecutive AAC assessments. As several patients deceased prior to the AAC2 assessment, the association between ΔAAC and adverse events is likely to be affected by the study design and should be interpreted with caution. The assessment of laboratory parameters’ associations with ΔAAC was based on a mean of several measurements performed every 3 months spanning the interval from study recruitment to the latter AAC imaging, increasing the statistical weight and reliability of our current findings.

In conclusion, our current data show for the first time that AAC progresses at a comparable rate in patients on different RRT modalities and patients continuing conservative care during a follow-up of 3 years. Furthermore, AAC is associated with mortality and MACEs. Plasma phosphorus and LVMI are independently associated with ΔAAC.

References

1 Foley RN, Murray AM, Li S, Herzog CA, Mc-Bean AM, Eggers PW, et al. Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States medicare population, 1998 to 1999. J Am Soc Nephrol. 2005 Feb;16(2):489–95.
2 Pencak P, Czerwieńska B, Ficek R, Wyskida K, Kujawa-Szewieczek A, Olszanecka-Glinianowicz M, et al. Calcification of coronary arteries and abdominal aorta in relation to traditional and novel risk factors of atherosclerosis in hemodialysis patients. BMC Nephrol. 2013 Jan;14:10.
3 KDIGO Work Group. Clinical practice guide-line for the evaluation and management of chronic kidney disease. Kidney Int Suppl. 2013 Jan;3(Suppl 3):1–150.
4 Davies MR, Hruska KA. Pathophysiological mechanisms of vascular calcification in end-stage renal disease. Kidney Int. 2001 Aug;60(2):472–9.
5 Peeters MJ, van den Brand JA, van Zuilen AD, Koster Y, Bots ML, Vervloet MG, et al. Abdominal aortic calcification in patients with CKD. J Nephrol. 2017 Feb;30(1):109–18.
6 Lewis JR, Schousboe JT, Lim WH, Wong G, Wilson KE, Zhu K, et al. Long-term atherosclerotic vascular disease risk and prognosis in elderly women with abdominal aortic calcification on lateral spine images captured during bone density testing: a prospective study. J Bone Miner Res. 2018 Jun;33(6):1001–10.
7 Niu Q, Hong Y, Lee CH, Men C, Zhao H, Zuo L. Abdominal aortic calcification can predict all-cause mortality and CV events in dialysis patients: a systematic review and meta-analysis. PLoS One. 2018 Sep;13(9):e0204526.
8 Imanishi K, Hatakeyama S, Yamamoto H, Okamoto A, Imai A, Yoneyama T, et al. Post-transplant renal function and cardiovascular events are closely associated with the aortic calcification index in renal transplant recipients. Transpl Proc. 2014;46(2):484–8.
9 Meneghini M, Regalia A, Alfieri C, Barretta F, Croci D, Gandolfo MT, et al. Calcium and osteoprotegerin levels predict the progression of the abdominal aortic calcifications after kidney transplantation. Transplantation. 2013 Jul;96(1):42–8.
10 Noordzij M, Cranenburg EM, Engelsman LF, Hermans MM, Boeschoten EW, Branden-burg VM, et al. Progression of aortic calcification is associated with disorders of mineral metabolism and mortality in chronic dialysis patients. Nephrol Dial Transplant. 2011 May;26(5):1662–9.
11 Yamamoto D, Suzuki S, Ishii H, Hirayama K, Harada K, Aoki T, et al. Predictors of abdominal aortic calcification progression in patients with chronic kidney disease without hemodialysis. Atherosclerosis. 2016 Oct;253:15–21.

12 Lankinen R, Hakamäki M, Metsärinne K, Koivuviita NS, Pärkkä JP, Hellman T, et al. Cardiovascular determinants of mortality in advanced chronic kidney disease. Am J Nephrol. 2020;51(9):726–35.

13 Kauppila LI, Polak JF, Cupples LA, Hannan MT, Kiel DP, Wilson PW. New indices to classify location, severity and progression of calcific lesions in the abdominal aorta: a 25-year follow-up study. Atherosclerosis. 1997 Jul;132(2):245–50.

14 Critchlow DE, Fligner MA. On distribution-free multiple comparisons in the one-way analysis of variance. Commun Stat Theor Methods. 1991;20:127–39.

15 Naganuma T, Takenoto Y, Uchida J, Nakatani T, Kabata D, Shintani A. Hypercalcemia is a risk factor for the progression of aortic calcification in kidney transplant recipients. Kidney Blood Press Res. 2019;44(4):823–34.

16 Inoue H, Shimizu S, Watanabe K, Kamiyama Y, Shima H, Nakase A, et al. Impact of trajectories of abdominal aortic calcification over 2 years on subsequent mortality: a 10-year longitudinal study. Nephrol Dial Transplant. 2018 Apr;33(4):676–83.

17 Kahwaji J, Bunnnapradist S, Hsu JW, Idroos ML, Dudek R. Cause of death with graft function among renal transplant recipients in an integrated healthcare system. Transplantation. 2011 Jan;91(2):225–30.

18 Ojo AO, Morales JM, Gonzalez-Molina M, Steffick DE, Luan FL, Merion RM, et al. Comparison of the long-term outcomes of kidney transplantation: USA versus Spain. Nephrol Dial Transplant. 2013 Jan;28(1):213–20.

19 Block GA, Klassen PS, Lazarus JM, Osthusen N, Lowrie EG, Chertow GM. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol. 2004 Aug;15(8):2208–18.

20 Toussaint ND, Pedagogos E, Lioufas NM, Elder GJ, Pascoe EM, Badve SV, et al. A randomized trial on the effect of phosphate reduction on vascular end points in CKD (IMP-ROVE-CKD). J Am Soc Nephrol. 2020 Nov;31(11):2653–66.

21 Kovesdy CP, Lu JL, Wall RM, Gyamblani G, Naseer A, Wallick A, et al. Changes with lanthanum carbonate, calcium acetate, and phosphorus restriction in CKD: a randomized controlled trial. Kidney Int Rep. 2018 Mar;3(4):897–904.

22 Chue CD, Townend JN, Moody WE, Zehnder D, Wall NA, Harper L, et al. Cardiovascular effects of sevelamer in stage 3 CKD. J Am Soc Nephrol. 2013 Apr;24(5):842–52.

23 Patel I, Bernard IM, Elder GJ. Sevelamer versus calcium-based binders for treatment of hyperphosphatemia in CKD: a meta-analysis of randomized controlled trials. Clin J Am Soc Nephrol. 2016 Feb;11(2):232–44.

24 Liu L, Wang Y, Chen H, Zhu X, Zhou L, Yang Y. The effects of non-calcium-based phosphate binders versus calcium-based phosphate binders on cardiovascular calcification and bone remodeling among dialysis patients: a meta-analysis of randomized trials. Ren Fail. 2014 Sep;36(8):1244–52.

25 Yildiz A, Memisoglu E, Ozlak H, Yazici H, Pusuroglu H, Akkaya V, et al. Atherosclerosis and vascular calcification are independent predictors of left ventricular hypertrophy in chronic haemodialysis patients. Nephrol Dial Transplant. 2005 Apr;20(4):760–7.